Abstract #2211
129Xe Gas-Transfer MRI RBC-to-Barrier Ratio in Post-Acute COVID19 Syndrome: Clinically-relevant?
Alexander M Matheson1, Harkiran K Kooner1, Elianna Bier2, Junlan Lu2, Bastiaan Driehuys2, Miranda Kirby3, Giles Santyr4,5, Mitchell S Albert6, Yurii Shepelytskyi6, Vira Grynko6, Sarah Svenningsen7,8, Alexei Ouriadov9, Inderdeep Dhaliwal10, J Michael Nicholson10, and Grace Parraga1,10
1Department of Medical Biophysics, Robarts Research Institute, Western University, London, ON, Canada, 2Center for In Vivo Microscopy, Duke University Medical Center, Durham, NC, United States, 3Department of Physics, Ryerson University, Toronto, ON, Canada, 4Hospital for Sick Children, Toronto, ON, Canada, 5Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada, 6Thunder Bay Regional Health Research Institute, Lakehead University, Thunder Bay, ON, Canada, 7Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada, 8St. Joseph's Healthcare, Hamilton, ON, Canada, 9Department of Physics and Astronomy, Western University, London, ON, Canada, 10Division of Respirology, Department of Medicine, Western University, London, ON, Canada
Synopsis
Post-acute COVID19 syndrome (PACS) is an umbrella term for a syndrome of symptoms persisting at least 12 weeks post COVID19 infection. Preliminary studies in PACS patients post-hospitalization revealed abnormally low 129Xe RBC-to-barrier ratios, but the clinical relevance of this is not well-understood. We acquired 129Xe gas-transfer MRI, spirometry, diffusing-capacity-of-the-lung for carbon-monoxide (DLCO) and same-day CT in 39 participants including 30 PACS and 9 never-COVID19 controls. The 129Xe MRI RBC-to-barrier ratio was significantly related to DLCO and significantly lower in both never-hospitalized and ever-hospitalized PACS patients compared to never-COVID19 controls.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
